Immunotherapy in multiple myeloma - Possibility or probability?

British Journal of Haematology

Volumn 130, Issue 3, 2005, Pages 344-362

  Harrison, S J ^a   Cook, G ^b,c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Dendritic cell and T cells; Immunotherapy; Multiple myeloma; Vaccine

Indexed keywords

ALEMTUZUMAB; CANCER VACCINE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MONOCLONAL ANTIBODY; MYELOMA VACCINE; MYELOTARG; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG;

CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; COLITIS; DENDRITIC CELL; HUMAN; HYPOTENSION; IMMUNE SYSTEM; IMMUNOTHERAPY; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; ADOPTIVE TRANSFER; DISEASE FREE SURVIVAL; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGY; LYMPHOCYTE TRANSFUSION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANTIBODIES, MONOCLONAL; CANCER VACCINES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE TRANSFUSION; MULTIPLE MYELOMA; T-LYMPHOCYTES;

EID: 24944449622     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05534.x     Document Type: Review

References (185)

1. Agrawal B. Krantz M.J. Reddish M.A. Longenecker B.M. (1998) Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nature Medicine, 4, 43 49.
2. Albert M.L. Sauter B. Bhardwaj N. (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature, 392, 86 89.
3. Aluvihare V.R. Kallikourdis M. Betz A.G. (2004) Regulatory T cells mediate maternal tolerance to the fetus. Nature Immunology, 5, 266 271.
4. Andrews D.M. Scalzo A.A. Yokoyama W.M. Smyth M.J. Degli-Esposti M.A. (2003) Functional interactions between dendritic cells and NK cells during viral infection. Nature Immunology, 4, 175 181.
5. Asano M. Toda M. Sakaguchi N. Sakaguchi S. (1996) Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. Journal of Experimental Medicine, 184, 387 396.
6. Austyn J.M. Larsen C.P. (1990) Migration patterns of dendritic leukocytes. Implications for transplantation. Transplantation, 49, 1 7.
7. Beckhove P. Witzens M. Choi C. Ho A.D. Goldschmidt H. Schirrmacher V. (2003) MUC1-reactive cytotoxic memory T cells in bone marrow of multiple myeloma patients. Blood, 102, Abstract no. 5227.
8. Bendandi M. Gocke C.D. Kobrin C.B. Benko F.A. Sternas L.A. Pennington R. Watson T.M. Reynolds C.W. Gause B.L. Duffey P.L. Jaffe E.S. Creekmore S.P. Longo D.L. Kwak L.W. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Medicine, 5, 1171 1177.
9. Bensinger W. Buckner C. Anasetti C. Clift R. Storb R. Barnett T. Chauncey T. Shulman H. Appelbaum F. (1996) Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood, 88, 2787 2793.
10. Bjorkstrand B.B. Ljungman P. Svensson H. Hermans J. Alegre A. Apperley J. Blade J. Carlson K. Cavo M. Ferrant A. Goldstone A.H. de Laurenzi A. Majolino I. Marcus R. Prentice H.G. Remes K. Samson D. Sureda A. Verdonck L.F. Volin L. Gahrton G. (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood, 88, 4711 4718.
11. Blair A. Rowbottom A.W. Browne S.J. Goulden N.J. Steward C.G. Oakhill A. Pamphilon D.H. (2001) An optimised biphasic culture system for the generation of functional dendritic cells from patients with acute lymphoblastic leukaemia at presentation and in clinical remission. Leukemia, 15, 1596 1603.
12. Bollard C.M. Savoldo B. Rooney C.M. Heslop H.E. (2003) Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematologica, 110, 139 148.
13. Borrello I. Biedrzycki B. Sheets N. George B. Racke F. Loper K. Noonan K. Donnelly A. Hege K. Levitski H.I. (2004) Autologous tumor combined with a GM-CSF-secreting cell line vaccine (GVAX®) following autologous stem cell transplant (ASCT) in multiple myeloma. Blood, 104, Abstract no. 440.
14. Boyer A. Andreu G. Romet-Lemonne J.L. Fridman W.H. Teillaud J.L. (1999) Generation of phagocytic MAK and MAC-DC for therapeutic use: characterization and in vitro functional properties. Experimental Hematology, 27, 751 761.
15. Brown R.D. Yuen E. Nelson M. Gibson J. Joshua D. (1997) The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia, 11, 1312 1317.
16. Brown R.D. Pope B. Murray A. Esdale W. Sze D.M. Gibson J. Ho P.J. Hart D. Joshua D. (2001) Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood, 98, 2992 2998.
17. Brown R. Murray A. Pope B. Sze D.M. Gibson J. Ho P.J. Hart D. Joshua D. (2004) Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. British Journal of Haematology, 125, 743 748.
18. Campbell J.D. Cook G. Robertson S.E. Fraser A. Boyd K.S. Gracie J.A. Franklin I.M. (2001) Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. Journal of Immunology, 167, 553 561.
19. Caux C. Dezutter-Dambuyant C. Schmitt D. Banchereau J. (1992) GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature, 360, 258 261.
20. Caux C. Massacrier C. Vanbervliet B. Dubois B. Van Kooten C. Durand I. Banchereau J. (1994) Activation of human dendritic cells through CD40 cross-linking. Journal of Experimental Medicine, 180, 1263 1272.
21. Caux C. Massacrier C. Dezutter-Dambuyant C. Vanbervliet B. Jacquet C. Schmitt D. Banchereau J. (1995) Human dendritic Langerhans cells generated in vitro from CD34+ progenitors can prime naive CD4+ T cells and process soluble antigen. Journal of Immunology, 155, 5427 5435.
22. Chan V.W. Kothakota S. Rohan M.C. Panganiban-Lustan L. Gardner J.P. Wachowicz M.S. Winter J.A. Williams L.T. (1999) Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells. Blood, 93, 3610 3616.
23. Chen S. Zani C. Khouri Y. Marasco W.A. (1995) Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Therapy, 2, 116 123.
24. Chiriva-Internati M. Liu Y. Weidanz J.A. Grizzi F. You H. Zhou W. Bumm K. Barlogie B. Mehta J.L. Hermonat P.L. (2003) Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood, 102, 3100 3107.
25. Coiffier B. Haioun C. Ketterer N. Engert A. Tilly H. Ma D. Johnson P. Lister A. Feuring-Buske M. Radford J.A. Capdeville R. Diehl V. Reyes F. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood, 92, 1927 1932.
26. Cook G. Campbell J.D. (1999) Immune regulation in multiple myeloma: the host-tumour conflict. Blood Reviews, 13, 151 162.
27. Cook G. Campbell J.D. Carr C.E. Boyd K.S. Franklin I.M. (1999) Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. Journal of Leukocyte Biology, 66, 981 988.
28. Corradini P. Voena C. Tarella C. Astolfi M. Ladetto M. Palumbo A. Van Lint M. Bacigalupo A. Santro A. Musso M. Majolino I. Boccadoro M. Pileri A. (1999) Molecular and clinical remission in multiple myeloma: role of autologous and allogeneic transplantation of haematopoietic cells. Journal of Clinical Oncology, 17, 208 215.
29. Corral L. Haslett P. Muller G. Chen R. Wong L. Ocampo C. Patterson R. Stirling D. Kaplan G. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. Journal of Immunology, 163, 380.
30. Coscia M. Mariani S. Battaglio S. Di Bello C. Fiore F. Foglietta M. Pileri A. Boccadoro M. Massaia M. (2004) Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia, 18, 139 145.
31. Crawley C. Lalancette M. Szydlo R. Gilleece M. Peggs K. Mackinnon S. Juliusson G. Ahlberg L. Nagler A. Shimoni A. Sureda A. Boiron J.-M. Einsele H. Chopra R. Carella A. Cavenagh J. Gratwohl A. Garban F. Zander A. Bjorkstrand B. Niederwieser D. Gahrton G. Apperley J.F. (2005) Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood, 105, 4532 4539.
32. Dabadghao S. Bergenbrant S. Anton D. He W. Holm G. Yi Q. (1998) Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. British Journal of Haematology, 100, 647 654.
33. Dauer M. Obermaier B. Herten J. Haerle C. Pohl K. Rothenfusser S. Schnurr M. Endres S. Eigler A. (2003) Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. Journal of Immunology, 170, 4069 4076.
34. De Vries I.J. Krooshoop D.J. Scharenborg N.M. Lesterhuis W.J. Diepstra J.H. Van Muijen G.N. Strijk S.P. Ruers T.J. Boerman O.C. Oyen W.J. Adema G.J. Punt C.J. Figdor C.G. (2003a) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Research, 63, 12 17.
35. De Vries I.J. Lesterhuis W.J. Scharenborg N.M. Engelen L.P. Ruiter D.J. Gerritsen M.J. Croockewit S. Britten C.M. Torensma R. Adema G.J. Figdor C.G. Punt C.J. (2003b) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clinical Cancer Research, 9, 5091 5100.
36. Dhodapkar M.V. Steinman R.M. Krasovsky J. Munz C. Bhardwaj N. (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. Journal of Experimental Medicine, 193, 233 238.
37. Dieu M.C. Vanbervliet B. Vicari A. Bridon J.M. Oldham E. Ait-Yahia S. Briere F. Zlotnik A. Lebecque S. Caux C. (1998) Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. Journal of Experimental Medicine, 188, 373 386.
38. Dimopoulos M.A. Zervas C. Zomas A. Hamilos G. Gika D. Efstathiou E. Panayiotidis P. Vervessou E. Anagnostopoulos N. Christakis J. (2002) Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia. Clinical Lymphoma, 3, 163 166.
39. Dong R. Cwynarski K. Entwistle A. Marelli-Berg F. Dazzi F. Simpson E. Goldman J.M. Melo J.V. Lechler R.I. Bellantuono I. Ridley A. Lombardi G. (2003) Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood, 101, 3560 3567.
40. Dudley M.E. Wunderlich J.R. Robbins P.F. Yang J.C. Hwu P. Schwartzentruber D.J. Topalian S.L. Sherry R. Restifo N.P. Hubicki A.M. Robinson M.R. Raffeld M. Duray P. Seipp C.A. Rogers-Freezer L. Morton K.E. Mavroukakis S.A. White D.E. Rosenberg S.A. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 298, 850 854.
41. Dzionek A. Fuchs A. Schmidt P. Cremer S. Zysk M. Miltenyi S. Buck D.W. Schmitz J. (2000) BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. Journal of Immunology, 165, 6037 6046.
42. EL-Sherbiny Y.M. Davies F.E. Cook G. Johnson R.J. Cullen M.J. Sah A. Rawstron A.C. Richards S.J. Morgan G.J. (2003) NK cell repertoire in myeloma and the impact of thalidomide. Blood, 102, abstract no. 1617.
43. Ellis J.H. Barber K.A. Tutt A Hale C Lewis A.P. Glennie M.J. Stevenson G.T. Crowe J.S. (1995) Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. Journal of Immunology, 155, 925 927.
44. Elrick L.J. Jorgensen H.G. Mountford J.C. Holyoake T.L. (2005) Punish the parent not the progeny. Blood, 105, 1862 1866.
45. Evans J.T. Cravens P. Lipsky P.E. Garcia J.V. (2000) Differentiation and expansion of lentivirus vector-marked dendritic cells derived from human CD34(+) cells. Human Gene Therapy, 11, 2483 2492.
46. Fearnley D.B. McLellan A.D. Mannering S.I. Hock B.D. Hart D.N. (1997) Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen-presenting cell function and immunotherapy. Blood, 89, 3708 3716.
47. Ferlazzo G. Munz C. (2004) NK cell compartments and their activation by dendritic cells. Journal of Immunology, 172, 1333 1339.
48. Ferlazzo G. Klein J. Paliard X. Wei W.Z. Galy A. (2000) Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells. Journal of Immunotherapy, 23, 48 58.
49. Ferlazzo G. Tsang M.L. Moretta L. Melioli G. Steinman R.M. Munz C. (2002) Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. Journal of Experimental Medicine, 195, 343 351.
50. Frohn C. Hoppner M. Schlenke P. Kirchner H. Koritke P. Luhm J. (2002) Anti-myeloma activity of natural killer lymphocytes. British Journal of Haematology, 119, 660 664.
51. Gale R.P. Horowitz M.M. Bortin M.M. (1989) IBMTR analysis of bone marrow transplants in acute leukaemia. Advisory Committee of the International Bone Marrow Transplant Registry (IBMTR). Bone Marrow Transplantation, 4, 83 84.
52. Galea-Lauri J. Wells J.W. Darling D. Harrison P. Farzaneh F. (2004) Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunology and Immunotherapy, 53, 963 977.
53. Garban F. Attal M. Rossi J.F. Payen C. Fegueux N. Sotto J.J. Intergroupe Francophone du M. (2001) Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation. Leukemia, 15, 642 646.
54. Gertz M.A. Anagnostopoulos A. Anderson K. Branagan A.R. Coleman M. Frankel S.R. Giralt S. Levine T. Munshi N. Pestronk A. Rajkumar V. Treon S.P. (2003) Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 30, 121 126.
55. Gimmi C.D. Morrison B.W. Mainprice B.A. Gribben J.G. Boussiotis V.A. Freeman G.J. Park S.Y. Watanabe M. Gong J. Hayes D.F. Kufe D.W. Nadler L.M. (1996) Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Medicine, 2, 1367 1370.
56. Glenchur H. Zinneman H.H. Hall W.H. (1959) A review of fifty-one cases of multiple myeloma; emphasis on pneumonia and other infections as complications. American Medical Association Archives of Internal Medicine, 103, 173 183.
57. Gluck W.L. Hurst D. Yuen A. Levine A.M. Dayton M.A. Gockerman J.P. Lucas J. Denis-Mize K. Tong B. Navis D. Difrancesco A. Milan S. Wilson S.E. Wolin M. (2004) Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clinical Cancer Research, 10, 2253 2264.
58. Gong J. Koido S. Chen D. Tanaka Y. Huang L. Avigan D. Anderson K. Ohno T. Kufe D. (2002) Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood, 99, 2512 2517.
59. Gonzalez M. San Miguel J.F. Gascon A. Moro M.J. Hernandez J.M. Ortega F. Jimenez R. Guerras L. Romero M. Casanova F. et al. (1992) Increased expression of natural-killer-associated and activation antigens in multiple myeloma. American Journal of Hematology, 39, 84 89.
60. Granucci F. Vizzardelli C. Pavelka N. Feau S. Persico M. Virzi E. Rescigno M. Moro G. Ricciardi-Castagnoli P. (2001) Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nature Immunology, 2, 882 888
61. Grimm, E.A., Mazumder, A., Zhang, H.Z. & Rosenberg S.A. (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. Journal of Experimental Medicine, 155, 1823 1841.
62. Hacein-Bey-Abina S. von Kalle C. Schmidt M. Le Deist F. Wulffraat N. McIntyre E. Radford I. Villeval J.L. Fraser C.C. Cavazzana-Calvo M. Fischer A. (2003a) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New England Journal of Medicine, 348, 255 256.
63. Hacein-Bey-Abina S. Von Kalle C. Schmidt M. McCormack M.P. Wulffraat N. Leboulch P. Lim A. Osborne C.S. Pawliuk R. Morillon E. Sorensen R. Forster A. Fraser P. Cohen J.I. de Saint Basile G. Alexander I. Wintergerst U. Frebourg T. Aurias A. Stoppa-Lyonnet D. Romana S. Radford-Weiss I. Gross F. Valensi F. Delabesse E. Macintyre E. Sigaux F. Soulier J. Leiva L.E. Wissler M. Prinz C. Rabbitts T.H. Le Deist F. Fischer A. Cavazzana-Calvo M. (2003b) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415 419.
64. Hao S. Bi X. Xu S. Wei Y. Wu X. Guo X. Carlsen S. Xiang J. (2004) Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Experimental Oncology, 26, 300 306.
65. Hemmi H. Takeuchi O. Kawai T. Kaisho T. Sato S. Sanjo H. Matsumoto M. Hoshino K. Wagner H. Takeda K. Akira S. (2000) A toll-like receptor recognizes bacterial DNA. Nature, 408, 740 745.
66. Hengel H. Lindner M. Wagner H. Heeg K. (1987) Frequency of herpes simplex virus-specific murine cytotoxic T lymphocyte precursors in mitogen- and antigen-driven primary in vitro T cell responses. Journal of Immunology, 139, 4196 4202.
67. Howard M. Spalk E. Choudhury K. Greten T. Schneck J. (1999) MHC-based diagnostics and therapeutics- clinical applications for disease linked genes. Immunology Today, 20, 155 198.
68. Hsu F.J. Caspar C.B. Czerwinski D. Kwak L.W. Liles T.M. Syrengelas A. Taidi-Laskowski B. Levy R. (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood, 89, 3129 3135.
69. Huff C.A. Jones R.J. (2002) Bone marrow transplantation for multiple myeloma: where we are today. Current Opinion in Oncology, 14, 147 151.
70. Hughes T.P. Economou K. Mackinnon S. Vlitos M. Arthur C.K. Guo A.P. Rassool F. Apperley J.F. Hows J. Goldman J.M. (1989) Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. British Journal of Haematology, 73, 462 467.
71. Jones R.J. (2003) Differentiation of cancer stem cells. Experimental Hematology, 31, S136.
72. Jones E. Dahm-Vicker M. Simon A.K. Green A. Powrie F. Cerundolo V. Gallimore A. (2002) Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunity, 2, 1.
73. Jonuleit H. Schmitt E. Steinbrink K. Enk A.H. (2001a) Dendritic cells as a tool to induce anergic and regulatory T cells. Trends in Immunology, 22, 394 400
74. Jonuleit, H., Giesecke-Tuettenberg, A., Tuting, T., Thurner-Schuler, B., Stuge, T.B., Paragnik, L., Kandemir, A., Lee, P.P., Schuler, G., Knop, J. & Enk A.H. (2001b) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. International Journal of Cancer, 93, 243 251.
75. Kim S.B. Baskar S. Kwak L.W. (2003) In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells. Leukemia and Lymphoma, 44, 1201 1208.
76. King C.A. Spellerberg M.B. Zhu D. Rice J. Sahota S.S. Thompsett A.R. Hamblin T.J. Radl J. Stevenson F.K. (1998) DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nature Medicine, 4, 1281 1286.
77. Kiss T.L. Spaner D. Daly A.S. Hasegawa W.S. Lipton J.H. Messner H.A. Chang H. (2003) Complete remission of tumour with interleukin 2 therapy in a patient with non-Hodgkin's lymphoma post allogeneic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis. British Journal of Haematology, 120, 523 525.
78. Kolb H. Mittermuller J. Clemm C. Holler E. Ledderose G. Brehm G. Heim M. Williams W. (1990) Donor leukocyte transfusions for the treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood, 76, 2462 2465.
79. Kwak L.W. Taub D.D. Duffey P.L. Bensinger W.I. Bryant E.M. Reynolds C.W. Longo D.L. (1995) Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet, 345, 1016 1020.
80. Li Y. Bendandi M. Deng Y. Dunbar C. Munshi N. Jagannath S. Kwak L.W. Lyerly H.K. (2000) Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood, 96, 2828 2833.
81. Lim S.H. Bailey-Wood R. (1999) Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. International Journal of Cancer, 83, 215 222.
82. Lim S.H. Zhang Y. Wang Z. Varadarajan R. Periman P. Esler W.V. (2004) Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency. Blood, 103, 1971 1972.
83. Liso A. Stockerl-Goldstein K.E. Auffermann-Gretzinger S. Benike C.J. Reichardt V. van Beckhoven A. Rajapaksa R. Engleman E.G. Blume K.G. Levy R. (2000) Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation, 6, 621 627.
84. Liu Y.J. Kanzler H. Soumelis V. Gilliet M. (2001) Dendritic cell lineage, plasticity and cross-regulation. Nature Immunology, 2, 585 589.
85. Ljunggren H.G. Karre K. (1990) In search of the 'missing self': MHC molecules and NK cell recognition. Immunology Today, 11, 237 244
86. Lokhorst, H.M., Schattenberg, A., Cornelissen, J.J., Thomas, L.L. & Verdonck L.F. (1997) Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood, 90, 4206 4211.
87. Lokhorst H.M. Schattenberg A. Cornelissen J.J. van Oers M.H. Fibbe W. Russell I. Donk N.W. Verdonck L.F. (2000) Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Journal of Clinical Oncology, 18, 3031 3037.
88. Lopez J.A. Bioley G. Turtle C.J. Pinzon-Charry A. Ho C.S. Vuckovic S. Crosbie G. Gilleece M. Jackson D.C. Munster D. Hart D.N. (2003) Single step enrichment of blood dendritic cells by positive immunoselection. Journal of Immunological Methods, 274, 47 61.
89. Lotze M.T. Grimm E.A. Mazumder A. Strausser J.L. Rosenberg S.A. (1981) Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Research, 41, 4420 4425.
90. Lotze M.T. Chang A.E. Seipp C.A. Simpson C. Vetto J.T. Rosenberg S.A. (1986) High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA, 256, 3117 3124.
91. Lowdell M.W. Koh M.B. (2000) Immunotherapy of AML: future directions. Journal of Clinical Pathology, 53, 49 54.
92. Lowdell M.W. Ray N. Craston R. Corbett T. Deane M. Prentice H.G. (1997) The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia. Bone Marrow Transplantation, 19, 891 897.
93. Lowdell M.W. Craston R. Prentice H.G. (1999) Generation of autologous immunity to acute myeloid leukaemia and maintenance of complete remission following interferon-alpha treatment. Cytokines Cellular and Molecular Therapy, 5, 119 121.
94. MacDonald K.P. Munster D.J. Clark G.J. Dzionek A. Schmitz J. Hart D.N. (2002) Characterization of human blood dendritic cell subsets. Blood, 100, 4512 4520.
95. Maraskovsky E. Brasel K. Teepe M. Roux E. Lyman S. Shortman K. McKenna H. (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. Journal of Experimental Medicine, 184, 1953 1962.
96. Mariani S. Coscia M. Even J. Peola S. Foglietta M. Boccadoro M. Sbaiz L. Restagno G. Pileri A. Massaia M. (2001) Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. British Journal of Haematology, 113, 1051 1059.
97. Mathe G. Amiel J.L. Schwarzenberg L. Cattan A. Schneider M. (1965) Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Research, 25, 1525 1531.
98. Matsui W. Huff C.A. Wang Q. Malehorn M.T. Barber J. Tanhehco Y. Smith B.D. Civin C.I. Jones R.J. (2004) Characterization of clonogenic multiple myeloma cells. Blood, 103, 2332 2336.
99. Matzinger P. (1998) An innate sense of danger. Seminars in Immunology, 10, 399 415.
100. Matzinger P. Guerder S. (1989) Does T-cell tolerance require a dedicated antigen-presenting cell Nature, 338, 74 76.
101. McCormack M. Rabbitts T. (2004) Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combine immunodeficiency. New England Journal of Medicine, 350, 913 922.
102. McLaughlin P. Grillo-Lopez A.J. Link B.K. Levy R. Czuczman M.S. Williams M.E. Heyman M.R. Bence-Bruckler I. White C.A. Cabanillas F. Jain V. Ho A.D. Lister J. Wey K. Shen D. Dallaire B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825 2833.
103. Mellor A.L. Baban B. Chandler P. Marshall B. Jhaver K. Hansen A. Koni P.A. Iwashima M. Munn D.H. (2003) Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. Journal of Immunology, 171, 1652 1655.
104. Miller M.J. Safrina O. Parker I. Cahalan M.D. (2004) Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes. Journal of Experimental Medicine, 200, 847 856.
105. Moretta L. Ferlazzo G. Mingari M.C. Melioli G. Moretta A. (2003) Human natural killer cell function and their interactions with dendritic cells. Vaccine, 21, S38 S42.
106. Morse M.A. Lyerly H.K. Li Y. (1999) The role of IL-13 in the generation of dendritic cells in vitro. Journal of Immunotherapy, 22, 506 513.
107. Morse M.A. Nair S. Fernandez-Casal M. Deng Y. St Peter M. Williams R. Hobeika A. Mosca P. Clay T. Cumming R.I. Fisher E. Clavien P. Proia A.D. Niedzwiecki D. Caron D. Lyerly H.K. (2000) Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. Journal of Clinical Oncology, 18, 3883 3893
108. Munn, D.H., Sharma, M.D., Lee, J.R., Jhaver, K.G., Johnson, T.S., Keskin, D.B., Marshall, B., Chandler, P., Antonia, S.J., Burgess, R., Slingluff, Jr, C.L. & Mellor A.L. (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science, 297, 1867 1870.
109. Musto P. Carella Jr., A.M. Greco M.M. Falcone A. Sanpaolo G. Bodenizza C. Cascavilla N. Melillo L. Carella A.M. (2003) Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. British Journal of Haematology, 123, 746 747
110. Osterborg, A., Yi, Q., Henriksson, L., Fagerberg, J., Bergenbrant, S., Jeddi-Tehrani, M., Ruden, U., Lefvert, A.K., Holm, G. & Mellstedt H. (1998) Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood, 91, 2459 2466.
111. Overwijk W.W. Theoret M.R. Finkelstein S.E. Surman D.R. de Jong L.A. Vyth-Dreese F.A. Dellemijn T.A. Antony P.A. Spiess P.J. Palmer D.C. Heimann D.M. Klebanoff C.A. Yu Z. Hwang L.N. Feigenbaum L. Kruisbeek A.M. Rosenberg S.A. Restifo N.P. (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. Journal of Experimental Medicine, 198, 569 580.
112. Oyama T. Ran S. Ishida T. Nadaf S. Kerr L. Carbone D.P. Gabrilovich D.I. (1998) Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. Journal of Immunology, 160, 1224 1232.
113. Perez-Simon J.A. Martino R. Alegre A. Tomas J.F. De Leon A. Caballero D. Sureda A. Sierra J. San Miguel J.F. (2003) Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. British Journal of Haematology, 121, 104 108.
114. Perri R.T. Hebbel R.P. Oken M.M. (1981) Influence of treatment and response status on infection risk in multiple myeloma. American Journal of Medicine, 71, 935 940.
115. Prabhala R. Neri P. Tassone P. Shammas M.A. Bae J. Cumming V.M. Allam C.K. Daley J.F. Desarneud F. Chauhan D. Blanchard E. Anderson K. Munshi N.C. (2004) Dysregulated CD4+ CD25+ T-regulatory cells and TLRs in myeloma. Blood, 104, abstract no. 2466.
116. Propato A. Cutrona G. Francavilla V. Ulivi M. Schiaffella E. Landt O. Dunbar R. Cerundolo V. Ferrarini M. Barnaba V. (2001) Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nature Medicine, 7, 807 813.
117. Qu C. Edwards E.W. Tacke F. Angeli V. Llodra J. Sanchez-Schmitz G. Garin A. Haque N.S. Peters W. van Rooijen N. Sanchez-Torres C. Bromberg J. Charo I.F. Jung S. Lira S.A. Randolph G.J. (2004) Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. Journal of Experimental Medicine, 200, 1231 1241.
118. Raitakari M. Brown R.D. Gibson J. Joshua D.E. (2003) T cells in myeloma. Hematological Oncology, 21, 33 42.
119. Raje N. Hideshima T. Davies F.E. Chauhan D. Treon S.P. Young G. Tai Y.T. Avigan D. Gong J. Schlossman R.L. Richardson P. Kufe D.W. Anderson K.C. (2004) Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. British Journal of Haematology, 125, 343 352.
120. Rasmussen T. Hansson L. Osterborg A. Johnsen H.E. Mellstedt H. (2003) Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood, 101, 4607 4610.
121. Ratta M. Fagnoni F. Curti A. Vescovini R. Sansoni P. Oliviero B. Fogli M. Ferri E. Della Cuna G.R. Tura S. Baccarani M. Lemoli R.M. (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood, 100, 230 237.
122. Ravaud A. Negrier S. Cany L. Merrouche Y. Le Guillou M. Blay J.Y. Clavel M. Gaston R. Oskam R. Philip T. (1994) Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. British Journal of Cancer, 69, 1111 1114.
123. Reichardt V. Okada C. Liso A. Benike C. Stockerl-Goldstein K. Engleman E. Blume K. Levy R. (1999) Idiotype vaccination using dendritic cells afterautologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood, 93, 2411 2419.
124. Reichardt V.L. Milazzo C. Brugger W. Einsele H. Kanz L. Brossart P. (2003) Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica, 88, 1139 1149.
125. Reid C.D. Stackpoole A. Meager A. Tikerpae J. (1992) Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. Journal of Immunology, 149, 2681 2688.
126. Rew S.B. Lopes L. Koishihara Y. Kosaka M. Ozaki S. Peggs K. Chain B. Yong K.L. (2003) Potent anti-tumour cytotoxic T lymphocytes directed against the myeloma antigen HM1.24. Blood, 102, abstract no. 380.
127. van Rhee F. Szmania S.M. Zhan F. Gupta S.K. Pomtree M. Lin P. Batchu R.B. Moreno A. Spagnoli G. Shaughnessy J. Tricot G.J. (2005) NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood, 105, 3934 3944.
128. Rice A. Hart D. (2002) Technology evaluation: APC-80200, Dendreon. Current Opinion in Molecular Therapeutics, 4, 523 527.
129. Ridgway D. (2003) The first 1000 dendritic cell vaccinees. Cancer Investigation, 21, 873 886.
130. Romani N. Reider D. Heuer M. Ebner S. Kampgen E. Eibl B. Niederwieser D. Schuler G. (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. Journal of Immunological Methods, 196, 137 151.
131. Rosenberg S.A. Lotze M.T. (1986) Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annual Review of Immunology, 4, 681 709.
132. Rosenberg S.A. Lotze M.T. Muul L.M. Leitman S. Chang A.E. Ettinghausen S.E. Matory Y.L. Skibber J.M. Shiloni E. Vetto J.T. Seipp C.A. Simpson C. Reichert C.M. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with
133. Rosenberg S.A. Lotze M.T. Muul L.M. Chang A.E. Avis F.P. Leitman S. Linehan W.M. Robertson C.N. Lee R.E. Rubin J.T. Seipp C.A. Simpson C.G. White D.E. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New England Journal of Medicine, 316, 889 897.
134. Rosenberg S.A. Yannelli J.R. Yang J.C. Topalian S.L. Schwartzentruber D.J. Weber J.S. Parkinson D.R. Seipp C.A. Einhorn J.H. White D.E. (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. Journal of the National Cancer Institute, 86, 1159 1166
135. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda M. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology, 155, 1151 1164.
136. Sakaguchi S. Sakaguchi N. Shimizu J. Yamazaki S. Sakihama T. Itoh M. Kuniyasu Y. Nomura T. Toda M. Takahashi T. (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunological Reviews, 182, 18 32.
137. Salama M. Nevill T. Marcellus D. Parker P. Johnson M. Kirk A. Porter D. Giralt S. Levine J.E. Drobyski W. Barrett A.J. Horowitz M. Collins R.H. (2000) Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplantation, 26, 1179 1184.
138. Santiago-Schwarz F. Belilos E. Diamond B. Carsons S.E. (1992) TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages. Journal of Leukocyte Biology, 52, 274 281.
139. Savelyeva N. Munday R. Spellerberg M.B. Lomonossoff G.P. Stevenson F.K. (2001) Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nature Biotechnology, 19, 760 764,.
140. Shigematsu H. Iwagaki H. Mizuno S. Akashi K. (2003) The majority of plasmacytoid dendritic cells originate from myeloid progenitors in murine hematopoiesis. Experimental Hematology, 31, S195.
141. Shimizu K. Fields R.C. Giedlin M. Mule J.J. (1999) Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proceedings of the National Academy of Sciences of the United States of America, 96, 2268 2273.
142. Singhal S. Mehta J. Desikan R. Ayers D. Roberson P. Eddlemon P. Munshi N. Anaissie E. Wilson C. Dhodapkar M. Zeddis J. Barlogie B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565 1571.
143. Singhal S. Safdar A. Chiang K.Y. Godder K. van Rhee F. Garner F. Foster B. Dubovsky D. Henslee-Downey P.J. Mehta J. (2000) Non-myeloablative allogeneic transplantation ('microallograft') for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis. Bone Marrow Transplantation, 26, 1231 1233.
144. Slavin S. Naparstek E. Nagler A. Ackerstein A. Samuel S. Kapelushnik J. Brautbar C. Or R. (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood, 87, 2195 2204.
145. Spellerberg M.B. Zhu D. Thompsett A. King C.A. Hamblin T.J. Stevenson F.K. (1997) DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. Journal of Immunology, 159, 1885 1892.
146. Steinman R.M. Cohn Z.A. (1973) Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology. Journal of Experimental Medicine, 137, 1142 1162.
147. Steinman R.M. Cohn Z.A. (1974) Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. Journal of Experimental Medicine, 139, 380 397.
148. Steinman R.M. Lustig D.S. Cohn Z.A. (1974) Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo. Journal of Experimental Medicine, 139, 1431 1445.
149. Steinman R.M. Adams J.C. Cohn Z.A. (1975) Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. Journal of Experimental Medicine, 141, 804 820.
150. Stevenson F.K. (2003) DNA vaccination: from the laboratory to the clinic. Hematology Journal, 4, S83.
151. Stevenson F.K. Ottensmeier C.H. Johnson P. Zhu D. Buchan S.L. McCann K.J. Roddick J.S. King A.T. McNicholl F. Savelyeva N. Rice J. (2004) DNA vaccines to attack cancer. Proceedings of the National Academy of Science of the United States of America, 101 (Suppl. 2 14646 14652.
152. Stritzke J. Zunkel T. Steinmann J. Schmitz N. Uharek L. Zeis M. (2003) Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model. British Journal of Haematology, 120, 27 35.
153. Strunk D. Rappersberger K. Egger C. Strobl H. Kromer E. Elbe A. Maurer D. Stingl G. (1996) Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood, 87, 1292 1302.
154. Sutmuller R.P. van Duivenvoorde L.M. van Elsas A. Schumacher T.N. Wildenberg M.E. Allison J.P. Toes R.E. Offringa R. Melief C.J. (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. Journal of Experimental Medicine, 194, 823 832.
155. Svensson M. Stockinger B. Wick M.J. (1997) Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. Journal of Immunology, 158, 4229 4236.
156. Sze D.M. Brown R.D. Yang S. Ho J.P. Gibson J. Fazekas de St Groth B. Basten A. Joshua D.E. (2003) Clonally expanded T cells in myeloma with a late memory/effector phenotype are associated with improved survival. Blood, 102, abstract no. 3451.
157. Szmania S.M. Rosen N.A. Freeman J. Batchu R.B. Barlogie B. Tricot G. Cottler-Fox M.H. Yi Q. Van Rhee F. (2003) Cryopreserved tumor protein loaded dendritic cell vaccines induce potent immune responses in patient with poor prognosis multiple myeloma. Blood, 102, abstract no. 1652.
158. Tarte K. Lu Z.Y. Fiol G. Legouffe E. Rossi J.F. Klein B. (1997) Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. Blood, 90, 3482 3495.
159. Tarte K. Fiol G. Rossi J.F. Klein B. (2000) Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia, 14, 2182 2192.
160. Thurnher M. Papesh C. Ramoner R. Gastl G. Bock G. Radmayr C. Klocker H. Bartsch G. (1997) In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy. Experimental Hematology, 25, 232 237.
161. Titzer S. Christensen O. Manzke O. Tesch H. Wolf J. Emmerich B. Carsten C. Diehl V. Bohlen H. (2000) Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. British Journal of Haematology, 108, 805 816.
162. Treon S.P. Maimonis P. Chauhan D. Anderson K.C. (1998) Soluble Muc-1 is elevated in multiple myeloma (MM) bone marrow (BM) plasma and inhibits T cell proliferation. Blood, 92, 411a.
163. Treon S.P. Agus T.B. Link B. Rodrigues G. Molina A. Lacy M.Q. Fisher D.C. Emmanouilides C. Richards A.I. Clark B. Lucas M.S. Schlossman R. Schenkein D. Lin B. Kimby E. Anderson K.C. Byrd J.C. (2001) CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. Journal of Immunotherapy, 24, 272 279.
164. Tricot G. Vesole D. Jagannath S Hilton J Munshi N Barlogie B. (1996) Graft-versus-myeloma effect: proof of principle. Blood, 87, 1196 1199.
165. Verdonck L.F. Petersen E.J. Lokhorst H.M. Nieuwenhuis H.K. Dekker A.W. Tilanus M.G. de Weger R.A. (1998) Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplantation, 22, 1057 1063.
166. Vij R. Borrello I. Martin T. Vescio R. Siegel D. Bashey A. Di Persio J.F. Berenson J. Ferrand C. Janmohamed F. Yuan V. Bouchard L. Berenson R.J. Bonyhadi M. Frohlich W. (2003) A phase I/II study of Xcellerated T cells after autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Blood, 102, abstract no. 139.
167. Vilches C. Parham P. (2002) KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annual Review of Immunology, 20, 217 251.
168. Villunger A. Egle A. Marschitz I. Kos M. Bock G. Ludwig H. Geley S. Kofler R. Greil R. (1997) Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood, 90, 12 20.
169. Wen Y.J. Barlogie B. Yi Q. (2001) Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood, 97, 1750 1755.
170. Wen Y.J. Min R. Tricot G. Barlogie B. Yi Q. (2002) Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood, 99, 3280 3285.
171. Williams N.S. Moore T.A. Schatzle J.D. Puzanov I.J. Sivakumar P.V. Zlotnik A. Bennett M. Kumar V. (1997) Generation of lytic natural killer 1.1+, Ly-49- cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates. Journal of Experimental Medicine, 186, 1609 1614.
172. Wood K.J. Sakaguchi S. (2003) Regulatory T cells in transplantation tolerance. Nature Reviews. Immunology, 3, 199 210.
173. Xu S. Koski G.K. Faries M. Bedrosian I. Mick R. Maeurer M. Cheever M.A. Cohen P.A. Czerniecki B.J. (2003) Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. Journal of Immunology, 171, 2251 2261.
174. Yang J.C. Haworth L. Sherry R.M. Hwu P. Schwartzentruber D.J. Topalian S.L. Steinberg S.M. Chen H.X. Rosenberg S.A. (2003a) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New England Journal of Medicine, 349, 427 434.
175. Yang J.C. Sherry R.M. Steinberg S.M. Topalian S.L. Schwartzentruber D.J. Hwu P. Seipp C.A. Rogers-Freezer L. Morton K.E. White D.E. Liewehr D.J. Merino M.J. Rosenberg S.A. (2003b) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. Journal of Clinical Oncology, 21, 3127 3132.
176. Yi Q. Osterborg A. Bergenbrant S. Mellstedt H. Holm G. Lefvert A.K. (1995) Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood, 86, 3043 3049.
177. Yi Q. Desikan R. Barlogie B. Munshi N. (2002) Optimizing dendritic cell-based immunotherapy in multiple myeloma. British Journal of Haematology, 117, 297 305.
178. Yi Q. Freeman M.E. Szmania S. Rosen N. Cottler-Fox M. Barlogie B. Tricot G. Van Rhee F. (2003) Intranodal vaccination with idiotype-pulsed dendritic cells induces potent and long-lasting cellular and humoral immune responses in myeloma patients. Blood, 102, abstract no. 5277.
179. Yiwen L. Bendandi M. Deng Y. Dunbar C. Munshi N. Jagannath S. Kwak L. Lyerly H. (2000) Tumour-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. Blood, 96, 2828 2833.
180. Zeis M. Frenzke H. Uharek L. Glass B. Schmitz N. M., Kronke Steinmann J. (1998) Dendritic cells pulsed with idiotypic determinants induce anti-tumour immunity against established multiple myeloma. Blood, 92, 4229.
181. Zeis M. Zunkel T. Steinmann J. Schmitz N. Uharek L. (2002) Enhanced antitumoral effectiveness of idiotype vaccination induced by the administration of Flt3 ligand combined with interleukin 2 against a murine myeloma. British Journal of Haematology, 117, 93 102.
182. Zheng C. Ostad M. Andersson M. Celsing F. Holm G. Sundblad A. (2002) Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma. British Journal of Haematology, 118, 778 785.
183. Zhu K. Shen Q. Ulrich M. Zheng M. (2000) Human monocyte-derived dendritic cells expressing both chemotactic cytokines IL-8, MCP-1, RANTES and their receptors, and their selective migration to these chemokines. Chinese Medical Journal, 113, 1124 1128.
184. Zinneman H.H. Hall W.H. (1954) Recurrent pneumonia in multiple myeloma and some observations on immunologic response. Annals of Internal Medicine, 41, 1152 1163.
185. Zinzani P.L. Pulsoni A. Perrotti A. Soverini S. Zaja F. De Renzo A. Storti S. Lauta V.M. Guardigni L. Gentilini P. Tucci A. Molinari A.L. Gobbi M. Falini B. Fattori P.P. Ciccone F. Alinari L. Martelli M. Pileri S. Tura S. Baccarani M. (2004) Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without Rituximab as front-line treatment for patients with follicular lymphoma. Journal of Clinical Oncology, 22, 2654 2661.